Sansheng Pharmaceutical HIF-PH Inhibitor HIF-117 Capsule (SSS17) Approved clinical

recently, it was revealed that the ThreePharmaceutical(http://HIF-PH inhibitor HIF-117 capsule (SSS17) was approved for clinical treatment of anemia in patients with chronic kidney diseaseThe physiological effects of low-oxygen inducing factors (HIF) not only increase the expression of erythropoietin, but also increase the expression of erythropoietin receptors and proteins that promote iron absorption and circulationOn December 18, 2018, FibroGen/AstraZeneca jointly developed a
new drug(http://Rosasta capsules approved for sale by NMPA, a product called Aretero, for the treatment of patients receiving dialysis due to chronic kidney disease (CKD) anemiaOn August 19, 2019, Rosa swashes in China has been approved for new indications for the treatment of anemia in patients with chronic kidney disease who have not received dialysisThe standard treatment commonly used for renal anemia is to replace erythropoietin (EPO hormone), red blood cell production stimulants such as afaibertin and add intravenous iron, subcutaneous injectionWhile Sansheng Pharmaceuticals in the domestic EPO market accounted for a large number of market share, Sansheng Pharmaceuticals 2019 half-year lying shows that its two recombinant erythropoietinproducts(http://Yibio and Sabor sales increased by 5.8%, the market share increased to 41.3%